Current Options in the Diagnosis and Treatment of Monkeypox

AbstractPurpose of ReviewThis review summarizes the current options for human monkeypox virus diagnostic testing, vaccination, and treatment.Recent FindingsInformation on non-lesion monkeypox virus diagnostic testing is limited to small studies with unclear sensitivities and specificities. Early data on the JYNNEOS vaccine has shown a lower incidence of monkeypox infection among vaccinated individuals. Drug options for human monkeypox, which include tecovirimat, cidofovir, brincidofovir, and vaccinia immune globulin intravenous, are limited without an FDA-approved medication and data on drug efficacy pending.SummaryData on non-lesion-based tests for human monkeypox infection, though limited, seems promising for certain clinical manifestations and to potentially screen asymptomatic patients if there is conclusive evidence of asymptomatic transmission. Vaccination with JYNNEOS appears effective in the prevention of monkeypox infection in early data. Of the limited medications available for monkeypox, tecovirimat ’s safety profile appears to be the best with data suggestive of efficacy though further conclusive evidence from clinical trials is lacking.
Source: Current Fungal Infection Reports - Category: Infectious Diseases Source Type: research